Vaccine against Ebola and Marburg successful in trial with monkeys

NewsGuard 100/100 Score

Scientists from Canada, the United States and France have developed the first vaccine to protect monkeys against Ebola and Marburg viruses.

The deadly Ebola fever killed as many as 120 people in the north-western Congo in 2003, and there have been over 255 deaths from Marburg in northern Angola since April this year.

Health workers in Angola are still fighting that outbreak of Marburg and cases of Ebola have been reported in Congo.

The Ebola and Marburg viruses cause haemorrhagic fever, a massive internal and external bleeding, which usually kills as many as 90% of those infected.

The study is encouraging news and will hopefully advance research into finding treatments for use in humans. There are presently no vaccines and no drugs available against the deadly viruses.

This latest research, which is an important breakthrough, clearly demonstrates the real potential for protection against these diseases.

In their study the scientists adapted another type of virus to carry proteins from the Ebola and Marburg viruses, the modified virus was then injected into macaque monkeys who were later exposed to the disease-causing pathogens.

Just a single injection appeared to completely protect the monkeys.

The researchers say that the initial data is so encouraging that the technique could be used against other emerging viruses and may even lead to a trial vaccine being developed for humans.

The study is published in the Nature Medicine journal.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New malaria vaccine strain shows promise in preclinical trials